Extend | the National Technology Transfer Biotech Hub的动态

Come Together: OncoDxRx’s PGA and OncoMRD Close the Gap of Precision Medicine to Benefit Non-Responders Among the key weapons deployed by cancer cells, the heterogeneity was, along with the drug resistance, the most worrying for the clinicians. This highly dynamic malignancy had, in fact, the potential to profoundly transform the geometry of cancer combat, by considerably reducing the reaction times of modern Dx and Rx, while being almost invulnerable to the targeted therapy and immunotherapy existing today. OncoDxRx’s?aim is to strengthen our precision Dx capability. This will lead to “transformative technologies regarding specific solutions that will allow filling gaps, reducing costs and shortening implementation times”. PGA (patient-derived gene expression-informed anticancer drug efficacy) and OncoMRD (monitoring residual disease)?technologies are equipped with numerous innovations that allow them to demonstrate differentiating capabilities in precision oncology areas. OncoDxRx’s one-of-a-kind tests are able to guide treatment selection and monitor drug efficacy while remaining cost- and time-efficiency thanks to the automated and streamline workflow. The integration of state-of-the-art mRNA biomarkers and data analytics also gives them superior predictive power and surveillance, detection and tracking capabilities. PGA and OncoMRD are exclusive and disruptive technologies. They bring unmatched high quality gene expression profiles derived directly from patients. Finally, these technologies come with digital computation that facilitate the delivery of customized reports in 5 days. ? #opportunities?#strategy?#programming?#design?#team?#research?#data?#health?#development?#collaboration?#projects?#testing?#immunotherapy?#cancer?#technology?#biotechnology?#healthcare?#medicine?#oncology?#precisionmedicine?#liquidbiopsy?#rna?#dna?#venturecapital?#startup?#immunooncology?#tcells?#innovation?#growth?#tech?#lifesciences?#biopharma?#oncodxrx

?? November Biotech Highlights: Financing & M&A Activity ?? November 2024 was a pivotal month for the biotech sector, showcasing resilience and growth through strategic investments and groundbreaking acquisitions. Here's a snapshot of the action: ?? Financing Highlights: · Metsera, advancing therapies for multiple sclerosis, secured $215M in Series B funding to accelerate clinical trials. · Enveda Biosciences raised $130M in Series C. The company is harnessing AI to discover nature-based medicines and is advancing multiple candidates, including ENV-294 for inflammatory conditions, into clinical development · Trace Neuroscience launched with a $101M Series A, focusing on genomic therapies for ALS and other neurodegenerative diseases. · TRexBio, focused on immune system modulation, raised $85M in its Series A to further its therapeutic platform. · Alentis Therapeutics raised an impressive $181.4 million in a Series D round to progress its Claudin-1-targeted ADC programs for solid tumors. · Erasca, Inc. raised $160M to accelerate Phase 3 oncology trials. · Cidara Therapeutics secured $105M for seasonal influenza immunotherapy (Phase 2). ?? Major M&A News: · Poseida Therapeutics, Inc. Therapeutics, a leader in allogeneic CAR-T therapies, was acquired by Roche in a deal valued at up to $1.5 billion. This acquisition bolsters Roche’s cell therapy pipeline, particularly in oncology and immunology. · Kate Therapeutics, focused on gene therapies for muscular dystrophy, was acquired by Astellas Pharma in a deal valued at $250 million upfront, plus milestone payments. ·Other strategic deals totaled over $2 billion, reflecting robust interest in AI-driven drug discovery and advanced gene-editing technologies. ?? Emerging Trends: 1?? M&A is increasingly focused on clinical-stage assets, with big pharma pursuing innovation in targeted and rare disease areas. 2?? Generalist capital is beginning to return, with investors optimistic about biotech’s recovery heading into 2025. 3?? The IPO market is showing signs of resilience, with strong performances from recent offering. As biotech continues to navigate economic headwinds, the focus on cutting-edge therapies and strategic consolidations is driving momentum. What are your thoughts on these developments? Which trends do you see shaping the sector in 2025? Let’s discuss! #Biotech #Innovation #Poseida #MergersAndAcquisitions #LifeSciences #Financing

Nothing new: my analysis below ?? reveals a significant gap in the capital raised by North American and European biotech companies in 2024. North American biotech firms are raising three times more than their European counterparts. - At Enabling Technologies, we're seeing North American start-ups leading the charge, particularly those working with AI-based drug design platforms, securing major funding for innovation. - Small molecules & antibodies continue to attract the largest investments. However, there’s a growing surge of interest in companies focused on gene & cell therapies and RNA-based drugs. - When it comes to disease areas, oncology and immunology are still top priorities. In Europe, these two areas make up 74% of total capital raised. In North America, however, they account for just 50%—indicating a broader diversification of investor interest across the Atlantic. The landscape is evolving, and both regions are navigating different priorities. As AI and novel therapies reshape the biotech industry, the flow of capital will be pivotal in driving innovation in healthcare. Source: Own elaboration based on media analysis from PR Newswire, Fiercebiotech, Labiotech, and BioPharma Dive. #Biotech #InvestmentTrends #DrugDesign #AI #Innovation #Oncology #Immunology #GeneTherapy #RNA #Biopharma #VentureCapital WA4STEAM

???Empowering Small and Midsize Biopharma: Driving the Next Wave of Innovation??? While large biopharma firms continue to invest heavily in R&D, it’s the small and midsize companies that are truly transforming the landscape. These agile players are expected to grow at a faster pace than their larger counterparts, holding a major share of the clinical trials and drug-development pipeline. Despite their size, these companies often face unique challenges like limited resources, lean infrastructure, and the pressure to rapidly scale. But their adaptability allows them to take bold steps—making a difference in fields such as oncology, rare diseases, and cell and gene therapies. ???Collaboration is Key:?By partnering with the right teams, small biopharma can bridge data gaps, optimize trial designs, and effectively communicate their innovations to regulators, payers, and healthcare providers. This approach not only supports successful product launches but also ensures that critical therapies reach the patients who need them most. At Optimax Access, we’re passionate about supporting these dynamic companies on their journey, helping them navigate the path from innovation to market success. #BiopharmaInnovation #ClinicalResearch #HEOR #MarketAccess #PatientCenteredCare #SmallBiopharma #HealthEconomics

The Global Precision Medicine market is rapidly transforming healthcare, leveraging personalized treatment approaches tailored to individual genetic, environmental, and lifestyle factors. With a projected market value of over $200 billion by 2033, the sector is growing at a compound annual growth rate (CAGR) of approximately 15%. Key players in the market include major pharmaceutical companies like Roche, Novartis, and Pfizer, alongside biotechnology firms like Illumina, Thermo Fisher Scientific, and Guardant Health, all of which are at the forefront of innovation. Technological advancements such as next-generation sequencing (NGS) and bioinformatics tools are accelerating growth. The integration of Artificial Intelligence (AI) and machine learning in diagnostics and drug development is creating a more robust and precise framework for personalized treatments. Recent collaborations and acquisitions are enabling new therapeutic solutions, further fueling market expansion. Notable industry developments include the increasing adoption of liquid biopsy techniques and advanced gene therapies, marking a shift toward minimally invasive diagnostic tools. Liquid biopsy in precision oncology, a groundbreaking advancement, allows for non-invasive cancer detection through blood samples. This technology enables real-time monitoring of genetic mutations and tumor evolution, providing an effective tool for personalized cancer treatment. It holds immense potential for early cancer detection, reducing the need for traditional tissue biopsy procedures, and enabling better patient outcomes. As precision oncology continues to evolve, liquid biopsy is poised to become an integral part of cancer diagnostics, revolutionizing the way cancers are treated and managed. The market dynamics reflect an ongoing trend toward targeted therapies, regulatory advancements, and an increasing focus on patient-centric solutions. #PrecisionMedicine #LiquidBiopsy #Oncology #NextGenSequencing #PersonalizedHealthcare #Biotech #Genomics #AIinHealthcare #CancerCare #HealthcareInnovation #Pharma #MedTech #TargetedTherapies #Koncepo?

TEVOGEN BIO’s AI-Powered Immunotherapy Gets a Major Boost ?? Big news in AI-driven biotech! Tevogen Bio just secured up to $10 million in non-dilutive grant funding, accelerating its mission to develop T-cell therapies for cancer and viral infections. The Breakthrough ? With this funding, Tevogen Bio is expanding Tevogen.AI, its artificial intelligence initiative, to revolutionize: ?? Drug discovery – Speeding up treatment development ?? Cost reduction – Making therapies more accessible ?? Patient accessibility – Bringing precision medicine to more people Microsoft & AI in Biopharma ???? TEVOGEN BIO is collaborating with Microsoft, recently co-hosting a panel at the JPMorgan Healthcare Conference featuring: ? David Rhew, M.D. – Global CMO, Microsoft ? Mittul Mehta – Head of Tevogen.AI They discussed how AI-driven drug discovery is the next frontier of medical innovation, reducing timelines and costs while improving patient care. Why This Matters ?? This funding comes at a critical time as Tevogen Bio advances CD8+ cytotoxic T cell therapies, offering off-the-shelf, unmodified precision treatments for large patient populations. Kudos to the TEVOGEN BIO team for pushing the boundaries of AI-driven immunotherapy! ?? #AI #Biotech #DrugDiscovery #Immunotherapy #HealthcareInnovation #LifeSciences #Therapeutics

It's halftime of the The 43th Annual JP Morgan Healthcare Conference Here are my top 4 (virtual) takeaways so far 1. ???????????????????? ??&?? ???????????????????? ?????????????????????? (????????????: ??????????????) Most notably, J&J is acquiring Intra-Cellular Therapies for nearly $15B, Eli Lilly acquired a breast cancer drug for $2.5B, and Boston Scientific is acquiring Bolt Medical for $664M ($443M guaranteed + $221M upon achieving certain milestones). 2. ???????????????????????? ???? ?????????????????????? ?????????????????????? ???????? ?????????????? (????????????: ?????????????????? ????????) Companies showcased progress in areas such as gene editing, AI-driven diagnostics, and novel drug delivery systems. Anavex Life Sciences presented promising Phase 2/3 data for blarcamesine, targeting Alzheimer's disease, reflecting the focus on innovative treatments. 3. ?????????? ???? ??????????-?????????? ???????? ?????? ???????????????????? ???????????? (????????????: ??????) Discussions have emphasized the importance of value-based care models and addressing healthcare disparities. Companies are exploring technology solutions to expand access and improve outcomes for underserved populations. 4. ???????????????? ???????????????? ?????? ???????????????????? ???????????????? & ?????????????? ???????????? (????????????: ?????????????????????? ???? ??????) Prospect Medical Holdings and Steward Healthcare both filing bankruptcy in 2024 doesn't help Healthcare Services M&A more broadly. That being said, we continue to have conversations with physicians and healthcare services business owners who are leaning on their peers that are benefiting from their private equity investment/partnership, as a proxy for exploring partnership options. What are your thoughts / takeaways so far? #jpmhealthcare2025 #mergersandacquisitions #health #care #investments

???????????????? ?????????????? ??????????????: 5 Key Mergers Shaping 2024 ?? In a year of tighter funding, biotech companies are making smart moves through strategic mergers, showing how 1+1 can equal 3. By combining expertise, pipelines, and resources, these 5 mergers stand out: 1?? ???????????? ???????????????? & ???????????? ???????????????????????? → ?????????????? ?????? ?? Combines Chroma’s cutting-edge gene-editing technology with Nvelop's precise DNA delivery system, focuses on epigenetic therapies for liver diseases and has subsequently raised $75million. 2?? ???????????????? ?????????????????????? & ?????????????? → ???????????????? ?????????????????????? ?? Combines gene therapies for rare diseases and pulmonary hypertension with expertise in GPCR-targeted biologics. This merger could deliver innovative solutions for rare genetic diseases and heart-related conditions and resulted in $130.7million private placement fundraising. 3?? ?????????????????? & ???????? ???????????????????????? → ??????????????????/???????? ???? ?? Combines REGiMMUNE's gene editing and monoclonal antibodies for immune-oncology with Kiji's iPSC-MSCs to enhance Treg function for autoimmune diseases. The new Treg titan is preparing for an IPO in 2025. 4??????????????????? ???????????? & ???????? ???????????????? → ???????? ???????????????? ?? Combines Opus gene therapy pipeline with Ocuphire Pharma's ophthalmic expertise, creating a leader in inherited retinal diseases. The company’s runway extends to 2026, with key clinical milestones in 2025. 5?? ?????? ?????????????????????????? & ???????????????????? → ??????/???????????????????? ?? Combines platforms for sleep disorders and stem cell therapies, diversifying the clinical pipeline, reducing financial risks, and strengthening market potential. The combined company plans to go public soon. ??????????: Ultimovacs ASA and Zelluna Immunotherapy AS have agreed to merge through a share exchange. Ultimovacs specializes in cancer vaccines, while Zelluna develops TCR-NK cell therapies for treating solid cancers. What are your thoughts? #celltherapy #genetherapy #biotech #CGTweekly

Some pretty interesting takeaways from BIO 2024 demonstrate the dynamism of the biotech business ecosystem: 1. AI in drug discovery isn't just promising; it's critical. 2. In oncology, patient impact and underserved areas are pivotal. 3. Global partnerships are reshaping biotech strategies. 4. Sustainability is no longer an option, but a business and health imperative. 5. The power of partnering is unmatched in propelling growth. Enjoy the quick read! (https://hubs.li/Q02GQNDc0) #PharmaInnovation #Sustainability #GlobalHealth #ArtificialIntelligence #StrategicPartnerships

Spencer Knight, In my work with biotechnology companies, law firms, investors, and executives in mergers and acquisitions (M&A) within the biotechnology sector, I have seen how M&A transactions have become a vital strategy for companies seeking to diversify their portfolios, particularly in response to patent expirations. When critical drug patents expire, companies face revenue declines as generics and biosimilars enter the market, intensifying competition and affecting pharmaceutical profitability. To overcome these challenges, M&A provides a strategic avenue for accessing cutting-edge technologies and emerging therapies. The biotechnology sector experienced a record-breaking $350 billion in transaction value, driven by the demand for innovations in precision medicine and breakthrough therapies. From a legal standpoint, M&A processes demand a comprehensive understanding of industry regulations, including patents, intellectual property (IP), and licensing agreements. Thorough due diligence is essential to assess the legal viability of acquisitions, ensuring the protection of acquired assets and compliance with third-party IP rights. A successful M&A strategy is not just about acquiring new technologies, but also about the seamless cultural and operational integration of acquired companies. This integration allows firms to maximize synergies, foster innovation, and maintain a competitive advantage in a highly regulated environment. The M&A strategy in biotechnology focuses not only on large-scale acquisitions but also on effective integration. Companies that combine deep biotechnology expertise with strong M&A execution are best positioned to lead the market, maximize investor value, and strengthen their leadership in the sector.